Pharmacie Centrale DES Hopitaux

Pharmacie Centrale des Hôpitaux (PCH) is an Algerian Public Establishment with Industrial and Commercial Character (EPIC), operating under the Ministry of Health. Established to supply pharmaceutical products to public health institutions across Algeria, PCH plays a pivotal role in the nation's healthcare system. The company manages a diverse portfolio of over 1,000 pharmaceutical product references, ensuring the availability of essential medications in public health facilities. (pch.dz)

Headquartered in Dar el Beida, Algiers, PCH operates a distribution network covering five regions: Algiers, Oran, Annaba, Biskra, and Bechar. This extensive network facilitates efficient delivery and storage of pharmaceutical products, maintaining quality control and product traceability. PCH's clientele includes both public and private entities, reflecting its comprehensive approach to healthcare provisioning. (pch.dz)

PCH's distribution network spans five key regions in Algeria: Algiers, Oran, Annaba, Biskra, and Bechar. This strategic geographic coverage ensures proximity to various public health establishments, enhancing the efficiency of pharmaceutical supply and distribution. The company's logistics capabilities are designed to maintain proper storage conditions and ensure timely delivery, adhering to quality control standards and product traceability requirements. (pch.dz)

In Algeria's pharmaceutical supply chain, PCH serves as a primary wholesaler and distributor, supplying pharmaceutical products to public health institutions nationwide. Its role is critical in ensuring the availability of essential medications in public health facilities, thereby supporting the national healthcare system. PCH's operations encompass the importation, storage, and distribution of pharmaceutical products, reflecting its integral position in the supply chain. (pch.dz)

PCH's sourcing strategy exhibits a high concentration, with the top five products accounting for 99.4% of its total import value from India. This concentration indicates a strategic focus on specific therapeutic areas, particularly oncology and advanced antibiotics. The substantial import values of products like Oxaliplatin ($2.3M) and Gemcitabine ($2.1M) underscore the company's emphasis on these categories. While this focused approach may streamline procurement and logistics, it also presents a risk if supply disruptions occur. The reliance on a limited number of products suggests that PCH's relationship with its suppliers is stable and well-established, as evidenced by the consistent import volumes over the years.

PCH's supply chain resilience is bolstered by its diversified supplier base, comprising 19 unique Indian pharmaceutical companies. This diversity mitigates the risks associated with dependency on a single supplier. The company's importation of 356 unique formulations further indicates a broad sourcing strategy, reducing vulnerability to supply chain disruptions. However, the concentration in specific therapeutic areas, such as oncology and advanced antibiotics, may expose PCH to risks if there are global shortages or regulatory changes affecting these products. Ensuring compliance with international quality standards and maintaining robust relationships with suppliers are essential for sustaining supply chain resilience.

PCH's concentrated sourcing pattern positions it as a key player in Algeria's oncology and advanced antibiotic markets. This focus allows the company to leverage economies of scale and establish strong supplier relationships. For Indian exporters, PCH represents a significant opportunity to supply high-demand pharmaceutical products to the Algerian market. However, potential suppliers must be prepared to meet PCH's stringent quality standards and navigate the regulatory landscape to establish successful partnerships.

In Algeria, the Ministry of Pharmaceutical Industry oversees the regulation of pharmaceutical imports. The regulatory framework governing these imports includes Decree No. 24, issued on October 1, 2025, which outlines the requirements, procedures, and compliance obligations for licensing pharmaceutical import establishments. This decree modernizes the application process and strengthens oversight of pharmaceutical import activities. Authorized import establishments are required to align with the new requirements within 12 months of the decree's publication in the Official Journal.

Import licensing requirements in Algeria are governed by Decree No. 24, which sets out the procedures for obtaining authorization to import pharmaceutical products. This includes the submission of an application file, processing and inspection procedures, and rules governing substantial modifications, renewal, and withdrawal of authorizations. Regarding Good Manufacturing Practice (GMP), Algeria recognizes certifications from reputable international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certificates from these recognized organizations to comply with Algerian regulations.

Pharmaceutical products imported into Algeria must undergo batch testing to ensure compliance with quality standards. Stability requirements are enforced to guarantee the efficacy and safety of medications throughout their shelf life. Labeling must be in Arabic and French, providing essential information such as dosage, indications, and storage conditions. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market. Compliance with these requirements is essential for market authorization and consumer safety.

In October 2025, Algeria's Ministry of Pharmaceutical Industry issued Decree No. 24, establishing new licensing requirements for pharmaceutical import establishments. This decree modernizes the application process and strengthens oversight of pharmaceutical import activities. Authorized import establishments are required to align with the new requirements within 12 months of the decree's publication in the Official Journal.

PCH's product strategy focuses on oncology and advanced antibiotics, with the top three categories being Oncology (53.2%), Advanced Oncology (43.4%), and Advanced Antibiotics (3.4%). This focus aligns with the high demand for cancer treatments and advanced antibiotic therapies in Algeria. The substantial import values of products like Oxaliplatin ($2.3M) and Gemcitabine ($2.1M) reflect PCH's commitment to providing essential medications in these therapeutic areas. Market demand, driven by the prevalence of cancer and infectious diseases, influences this strategic focus.

PCH's sourcing strategy emphasizes generic drug procurement, with a preference for formulations that meet international quality standards. India plays a significant role in PCH's overall procurement, supplying a diverse range of pharmaceutical products. The company's importation of 356 unique formulations from 19 Indian suppliers indicates a broad and diversified sourcing approach, reducing dependency on a single supplier and enhancing supply chain resilience.

Based on its product mix, PCH serves the hospital and government tender segments of the Algerian market. By supplying essential medications to public health institutions, PCH ensures the availability of critical treatments in hospitals and clinics across the country. Its focus on oncology and advanced antibiotics positions the company as a key supplier in these high-demand therapeutic areas.

There is a realistic opportunity for new Indian suppliers to partner with PCH, given the company's substantial import volumes and reliance on Indian pharmaceutical products. Potential suppliers should focus on oncology and advanced antibiotic formulations to align with PCH's strategic focus. Ensuring compliance with Algerian regulatory requirements, including GMP certifications and quality standards, is essential for establishing successful partnerships.

Indian exporters seeking to supply PCH must obtain GMP certifications from recognized international bodies such as EU GMP, WHO GMP, or PIC/S. Additionally, compliance with Algerian import licensing requirements, including the submission of an application file and adherence to inspection procedures, is mandatory. Products must meet quality standards, undergo batch testing, and adhere to labeling requirements in Arabic and French. Serialization mandates must also be fulfilled to ensure product traceability.

To build a relationship with PCH, Indian exporters should initiate contact through formal channels, providing detailed product information and demonstrating compliance with Algerian regulatory requirements. Participating in tenders and responding to procurement notices issued by PCH can facilitate entry into the Algerian market. Developing a comprehensive regulatory filing strategy, including the submission of necessary documentation and certifications, is crucial. Understanding the regulatory timeline and aligning with PCH's procurement cycles will enhance the likelihood of successful collaboration.